Clinical Trial Update: Rosiglitazone on Microalbuminuria in Type 2 Diabetics [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rosiglitazone for microalbuminuria in type 2 diabetes has completed. The provided excerpt does not include trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED